What is the debt of Immutep this year?
Immutep has a debt level of -122.19 AUD this year.
Immutep Debt 2024
Immutep Debt
-122.19 AUD
Ticker
IMM.AX
ISIN
AU000000IMM6
WKN
A2H81H
In 2024, Immutep's total debt was -122.19 AUD, a 56.13% change from the -78.26 AUD total debt recorded in the previous year.
Immutep Aktienanalyse
What does Immutep do?
Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. The company was founded in 2001 and is headquartered in Sydney, Australia. The history of Immutep began with the discovery of a new type of T-cell receptor, known as lymphocyte activation gene-3 (LAG-3) receptors, which are involved in the activation of T-cells. The company used this knowledge to develop a platform of immunotherapeutics based on the stimulation of LAG-3 receptors, with the goal of enhancing the body's immune response against cancer and autoimmune diseases. Immutep's business model is based on the development and commercialization of immunotherapeutics that target LAG-3 receptors. The company focuses on the clinical development of therapeutics targeting various stages of cancer, such as lung cancer, prostate cancer, and breast cancer. Additionally, the company is also developing therapeutics for the treatment of autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus, and Crohn's disease. Immutep is divided into various divisions to coordinate its activities in the areas of research and clinical development. These divisions include clinical development, research and development, and the production of immunotherapeutics. In the clinical development division, Immutep focuses on demonstrating the safety and efficacy of its immunotherapeutics in the treatment of cancer and autoimmune diseases. The company conducts clinical trials to evaluate the effectiveness of its therapeutics and obtain regulatory approval. Immutep's research and development department focuses on developing innovative immunotherapeutics based on LAG-3 receptors. The company has developed several patented technologies that enhance the effectiveness of the therapeutics and increase the body's tolerance to them. Immutep also operates a production division specializing in the manufacturing of immunotherapeutics. The company has production facilities in Europe and Asia, allowing it to distribute its therapeutics worldwide. The company offers a range of immunotherapeutics based on the stimulation of LAG-3 receptors. These therapeutics have been specifically developed for the treatment of cancer and autoimmune diseases and have the potential to enhance the body's immune response against these conditions. Immutep's products include IMP321, an immunotherapeutic specifically developed for the treatment of prostate cancer, and IMP701, an immunotherapeutic specifically developed for the treatment of lung cancer. Additionally, the company has several new therapeutics in clinical development, including IMP761 for the treatment of systemic lupus erythematosus and IMP731 for the treatment of Crohn's disease. Immutep is a leading company in the development of immunotherapeutics based on LAG-3 receptors. The company has a strong pipeline of therapeutics in clinical development and is well-positioned to benefit from the growing demand for immunotherapeutics for the treatment of cancer and autoimmune diseases. With its patented technologies and expertise in clinical development of immunotherapeutics, Immutep is well-equipped to grow and solidify its position as a leading company in this field. Immutep ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding Immutep's Debt Structure
Immutep's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing Immutep's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to Immutep’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in Immutep’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about Immutep stock
What was the debt of Immutep compared to the previous year?
The debt of Immutep has increased by 56.13% compared to the previous year increased.
What are the consequences of high debt for investors in Immutep?
High debt can pose a risk for investors of Immutep, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of Immutep?
Low debt means that Immutep has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from Immutep affect the company?
An increase in debt of Immutep can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of Immutep affect the company?
A reduction in debt of Immutep can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of Immutep?
Some factors that can influence the debt of Immutep include investments, acquisitions, operating costs, and revenue development.
Why are the debts of Immutep so important for investors?
The debts of Immutep are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can Immutep take to change the debt?
To change the debt, Immutep can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does Immutep pay?
Over the past 12 months, Immutep paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immutep is expected to pay a dividend of 0 AUD.
What is the dividend yield of Immutep?
The current dividend yield of Immutep is .
When does Immutep pay dividends?
Immutep pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immutep?
Immutep paid dividends every year for the past 0 years.
What is the dividend of Immutep?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immutep located?
Immutep is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immutep kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immutep from 8/26/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.
When did Immutep pay the last dividend?
The last dividend was paid out on 8/26/2024.
What was the dividend of Immutep in the year 2023?
In the year 2023, Immutep distributed 0 AUD as dividends.
In which currency does Immutep pay out the dividend?
The dividends of Immutep are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immutep
Our stock analysis for Immutep Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immutep Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
